Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Association ofHLA-C*06:02Status With Differential Response to Ustekinumab in Patients With Psoriasis

17 Apr 2019

Abstract excerpt

Importance: Previous research showed a differential response to ustekinumab therapy based on HLA-C*06:02 status in patients with psoriasis but consisted mostly of small (and sometimes inconclusive) cohort studies. Objective: To assess whether HLA-C*06:02 status is associated with a differential response to ustekinumab therapy in patients with psoriasis through a systematic review and a meta-analysis of available...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Dermatology and Skin Diseases
Share to Psoriasis: Treatment and Pathogenesis
Share to Spondyloarthritis Studies and Treatments

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 30994858
DOI: 10.1001/jamadermatol.2019.0098

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Association ofHLA-C*06:02Status With Differential Response to Ustekinumab in Patients With PsoriasisPMID 30994858Read ↗

Role of the HLA-C*06 allele in clinical response to ustekinumab: evidence from real life in a large cohort of European patients.Semantic proximity Read ↗

HLA-C*06 and response to ustekinumab in Caucasian patients with psoriasis: Outcome and long-term follow-upSemantic proximity Read ↗

HLA-C*06:02 Allele and Response to IL-12/23 Inhibition: Results from the Ustekinumab Phase 3 Psoriasis Program.Semantic proximity Read ↗

Association between HLA-Cw*0602 polymorphism and psoriasis risk: a meta-analysis.Semantic proximity Read ↗

HLA-C*06 and psoriasis: susceptibility, phenotype, course and response to treatment.Semantic proximity Read ↗

Human Leukocyte Antigen-Class I Alleles and the Autoreactive T Cell Response in Psoriasis Pathogenesis.Semantic proximity Read ↗

HLA-Cw6 and psoriasis.Semantic proximity Read ↗

Distinct Clinical Differences Between HLA-Cw*0602 Positive and Negative Psoriasis Patients – An Analysis of 1019 HLA-C- and HLA-B-Typed PatientsSemantic proximity Read ↗

Differences in Clinical Features and Comorbid Burden between HLA-C∗06:02 Carrier Groups in >9,000 People with Psoriasis.Semantic proximity Read ↗

Pharmacogenetics Update on Biologic Therapy in PsoriasisSemantic proximity Read ↗

Genetic Influence on Treatment Response in Psoriasis: New Insights into Personalized Medicine.Semantic proximity Read ↗

Cross-sectional study reveals that HLA-C*07:02 is a potential biomarker of early onset/lesion severity of psoriasis.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.